Conatus Pharmaceuticals is a biotechnology company focused on the development and commercialization of novel medicines to treat chronic diseases with significant unmet need. The Company's lead in-licensed compound, emricasan, is being developed in collaboration with Novartis for the treatment of patients with NASH-driven chronic liver diseases. In addition, Conatus' lead internally developed compound, CTS-2090, is targeting the treatment of patients with chronic diseases involving inflammasome pathways. Source
No articles found.
Omeros is a commercial-stage biopharmaceutical company committed to discovering, d...
Omeros is a commercial-stage biopharmaceutical ...
Kumba Health is an online platform connecting doctors with patients. Kumba Health ...
Kumba Health is an online platform connecting d...
Sensus Healthcare, Inc. (NASDAQ: SRTS; SRTSW) is a medical device company that is ...
Sensus Healthcare, Inc. (NASDAQ: SRTS; SRTSW) i...
St. Renatus, LLC, named after the patron saint of anesthesia, is a privately held ...
St. Renatus, LLC, named after the patron saint ...
Forward Pharma A/S is a Danish biopharmaceutical company that commenced developmen...
Forward Pharma A/S is a Danish biopharmaceutica...
Atreca is a biotechnology company developing novel therapeutics drawn from human i...
Atreca is a biotechnology company developing no...
Madrigal Pharmaceuticals is a clinical-stage biopharmaceutical company pursuing no...
Madrigal Pharmaceuticals is a clinical-stage bi...
Join the National Investor Network and get the latest information with your interests in mind.